Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

globenewswire.com - Nxera Pharma - Nxera Pharma Achieves Second Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases
Nxera Pharma Achieves Second Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases
GlobeNewswire

Tokyo, Japan and Cambridge, UK, 09 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it has achieved a second development milestone under its multi-target collaboration…

seekingalpha.com - Nelson Alves - Paysign Stock: The Market Is Finally Repricing A Pharma Margin Story (NASDAQ:PAYS)
Paysign Stock: The Market Is Finally Repricing A Pharma Margin Story (NASDAQ:PAYS)
Seeking Alpha

Paysign is evolving beyond a niche prepaid card processor, with patient affordability now driving higher-margin growth. 2025 results highlight a 40.5% revenue increase to $82M, with pharma revenue surging to $33.9M and gross margin expanding to…

marketwatch.com - Avalyn Pharma Files for IPO, Applied to List on Nasdaq Global Market Under the Symbol AVLN
Avalyn Pharma Files for IPO, Applied to List on Nasdaq Global Market Under the Symbol AVLN
MarketWatch

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client…

axios.com - Peter Sullivan - Pharma fallout from Iran war won't end with ceasefire
Pharma fallout from Iran war won't end with ceasefire
Axios

The Iran war is highlighting the fragile nature of global drug supply chains as disruptions ripple far beyond the Persian Gulf. Why it matters: Even if the ceasefire holds, disruptions to air cargo and the Strait of Hormuz bring the threat of…

afr.com - Sally Patten - This exec sold his start-up to big pharma. Now he has a bigger goal
This exec sold his start-up to big pharma. Now he has a bigger goal
Australian Financial Review

Manny Simons, the managing director of pharmaceuticals behemoth Eli Lilly in Australia and New Zealand, is something of a polymath. He has an undergraduate degree in neuroscience and music from Harvard University and a PhD in biomedical engineering…

indianexpress.com - Reuters - How a lobbying firm tied to Trump Jr helped Chinese pharma company beat US national security challenge
How a lobbying firm tied to Trump Jr helped Chinese pharma company beat US national security challenge
The Indian Express

A lobbying firm led by an associate of Donald Trump Jr. helped a Chinese pharmaceutical company secure access to senior US officials as it fought off a national security challenge from an American startup, news agency Reuters reported, citing the…

newswire.ca - Groupe LSL PHARMA INC. - JUNO OTC, A WHOLLY-OWNED SUBSIDIARY OF LSL PHARMA GROUP, SIGNS BINDING TERM SHEET WITH INSTAPILL PRIVATE LIMITED TO SUPPLY PRIVATE LABEL LORATADINE 10 MG RDT IN CANADA
JUNO OTC, A WHOLLY-OWNED SUBSIDIARY OF LSL PHARMA GROUP, SIGNS BINDING TERM SHEET WITH INSTAPILL PRIVATE LIMITED TO SUPPLY PRIVATE LABEL LORATADINE 10 MG RDT IN CANADA
CNW

The commercial launch is planned for June 2027 subject to Health Canada approval BOUCHERVILLE, QC, April 9, 2026 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL) ('LSL Pharma' or the 'Company'), a Canadian integrated pharmaceutical company, today…

thehindubusinessline.com - US market to dent India pharma earnings even as domestic growth remains firm: Report
US market to dent India pharma earnings even as domestic growth remains firm: Report
BusinessLine

India's pharmaceutical sector is likely to witness steady domestic growth but continued pressure in the US market in the fourth quarter of FY26, according to a report by Nuvama Institutional Equities. The report noted that while the domestic…

statnews.com - Ed Silverman - Pharmalittle: We're reading about top pharma lobbyist stepping down, genes and GLP-1 drugs, and more
Pharmalittle: We're reading about top pharma lobbyist stepping down, genes and GLP-1 drugs, and more
STAT

Top of the morning to you, and a fine one it is. Sunny skies and mild breezes are enveloping the Pharmalot campus once again. And to celebrate, we are brewing still more cups of stimulation and inviting you to join us. Our choice today is Jack…

marketbeat.com - Brokers Set Expectations for Innate Pharma FY2030 Earnings
Brokers Set Expectations for Innate Pharma FY2030 Earnings
MarketBeat

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA - Free Report) - Equities researchers at HC Wainwright issued their FY2030 EPS estimates for Innate Pharma in a research report issued on Tuesday, April 7th. HC Wainwright analyst S. Ramakanth expects…

seekingalpha.com - Bhavneesh Sharma - Structure Therapeutics: The Oral Obesity Inflection, Best-In-Class Efficacy
Structure Therapeutics: The Oral Obesity Inflection, Best-In-Class Efficacy
Seeking Alpha

Structure Therapeutics (GPCR) is initiated with a BUY rating and $110 price target, reflecting a 101% upside from current levels. Aleniglipron, GPCR's oral GLP-1 agonist, demonstrated 16.3% placebo-adjusted weight loss at 44 weeks with superior…

marketbeat.com - Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)
MarketBeat

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in…

bangordailynews.com - Reuters - Chinese firm hired lobbyists with ties to Don Jr, then scored a win in Washington
Chinese firm hired lobbyists with ties to Don Jr, then scored a win in Washington
Bangor Daily News

Never miss a headline. Support local news and the team that keeps you informed when you subscribe. Subscribe for $49 today. WASHINGTON — A lobbying firm led by one of Donald Trump Jr.'s hunting buddies helped a Chinese company make its case…

rediff.com - Sohini Das - India Pharmaceutical Market Q4 FY26 Growth: Chronic Therapies Drive Value & Volume Recovery
India Pharmaceutical Market Q4 FY26 Growth: Chronic Therapies Drive Value & Volume Recovery
Rediff.com

India's domestic pharmaceutical market experienced its strongest Q4 growth in five quarters during FY26, propelled by a notable volume recovery and a significant structural shift towards value-driven chronic and sub-chronic therapies. India's…

thehindubusinessline.com - Nifty Prediction Today - April 9, 2026: Nifty futures: Bears gathering strength
Nifty Prediction Today - April 9, 2026: Nifty futures: Bears gathering strength
BusinessLine

Nifty 50 began today's session with a gap-down at 23,909 compared to yesterday's close of 23,997. The index fell further after opening and is now trading at 23,820, down 0.7 per cent. The advance/decline ratio of Nifty 50 now stands at 19/31…

Receive a Daily briefing on Pharma Industry News

Get Started